The inhibitory effect of 4-MU on HAS2/3, combined with its antitumor activity and effects on lipid metabolic pathways, provides a new potential direction for the treatment of HCC and the development of novel tumor therapeutic strategies. The gene discussed is HAS2; the disease is hepatocellular carcinoma.